A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


July 6, 2012

Hep C Treatment Failure Can Still Mean Less Liver Inflammation

Hepatitis C treatment is typically seen as an all-or-nothing approach—nothing short of a sustained virologic response (SVR), or cure, will benefit people living with the virus. New data, however, suggest that even among those who don’t achieve an SVR, but who do see a substantial drop in hep C viral loads during treatment, there may be a reduction in inflammation associated with liver disease.

This encouraging finding, published ahead of print by the American Journal of Gastroenterology, is based on data from an older 1.050-patient clinical trial dubbed the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) study.

The primary goal of HALT-C was to determine whether 3.5 years of ongoing treatment with pegylated interferon (peg-IFN) monotherapy could slow liver disease progression—notably the development of liver cancer, liver failure or death—in people living with hepatitis C virus (HCV) who weren’t able to achieve an SVR using peg-IFN plus ribavirin.

According to the original results from the study, published in the journal Gastroenterology in January 2009, those who continued on long-term maintenance therapy with peg-IFN were no less likely to experience serious liver disease or death than those who did not receive additional treatment.

What remained unclear, however, is whether failed treatment—either during the peg-IFN/ribavirin “lead-in” period or during the long peg-IFN monotherapy maintenance period—was a complete wash for people who remained uncured of their infection.

In turn, study investigator Chihiro Morishima, MD, of the University of Washington in Seattle and her colleagues turned their attention to 834 participants from HALT-C who had liver biopsy results before starting peg-IFN/ribavirin treatment and then 1.5 years after being randomized to either peg-IFN maintenance therapy or no therapy with observation.

Morishima’s team used the biopsy specimens to look for changes in fibrosis scores and in histology activity index (HAI) scores—a measure of inflammation, which can lead to scarring of the liver.

Looking specifically at 657 patients who received full-dose peg-IFN and ribavirin lead-in therapy, HAI improvements were noted in the biopsy samples collected 1.5 years after being randomized in the study.

The improvements were highly statistically significant in one particular group of patients, dubbed responder relapsers, who saw their HCV viral loads reduced substantially during treatment but were unable to maintain an undetectable viral load after stopping therapy. These statistically significant improvements in HAI scores were just as likely to be seen in those who didn’t receive peg-IFN maintenance therapy compared with those who did.

Among all 834 patients followed for an average of six years, Morishima and her colleagues reported that those who achieved HAI improvements as a result of treatment were more likely to see other improvements as well. For example, among those with moderate-to-severe fibrosis at baseline, those with improved HAI scores at the 1.5-year mark had less liver fibrosis progression than those who didn’t experience HAI improvements.

In conclusion, the authors explain, there may still be advantages to failed treatment, notably among responder-relapsers. “Reduced hepatic inflammation,” they write, “was associated with profound virological suppression during lead-in treatment with full-dose peginterferon/ribavirin and with decreased fibrosis progression and clinical outcomes, independent of randomized [maintenance] treatment.”

Search: halt-c, hepatitis, hcv, svr, cure, inflammation, interferon, maintenance, hai, fibrosis

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.